Praxis Precision Medicines, Inc.
PRAXNASDAQHealthcare● Active
$252.67
$-1.33(-0.52%)
Market Cap$5.3B
P/E Ratio—
52W High$366.52
52W Low$37.19
Praxis Precision Medicines, Inc. (PRAX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PRAX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$3.20
Est. -$3.58 · +10.6%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
PRAX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | -$3.68 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$3.58 | -$3.20 | +10.6% | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 19, 2026 | -$3.13 | -$3.50 | -12.0% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$3.45 | -$3.36 | +2.6% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 4, 2025 | -$3.40 | -$3.31 | +2.6% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 2, 2025 | -$3.20 | -$3.29 | -2.8% | — | $0.00B | — |
| ▼ Q1 FY2025 | Feb 28, 2025 | -$2.76 | -$2.94 | -6.5% | $0.01B | $0.00B | +2405.4% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$2.01 | -$2.75 | -36.8% | $0.00B | $0.00B | -17.3% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$3.68
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$3.20
EPS Est.
-$3.58
EPS Surpr.
+10.6%
Revenue
—
Q1 FY2026
Feb 19, 2026Miss
EPS Actual
-$3.50
EPS Est.
-$3.13
EPS Surpr.
-12.0%
Revenue
—
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$3.36
EPS Est.
-$3.45
EPS Surpr.
+2.6%
Revenue
—
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
-$3.31
EPS Est.
-$3.40
EPS Surpr.
+2.6%
Revenue
—
Q2 FY2025
May 2, 2025Miss
EPS Actual
-$3.29
EPS Est.
-$3.20
EPS Surpr.
-2.8%
Revenue
—
Q1 FY2025
Feb 28, 2025Miss
EPS Actual
-$2.94
EPS Est.
-$2.76
EPS Surpr.
-6.5%
Revenue
$0.01B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$2.75
EPS Est.
-$2.01
EPS Surpr.
-36.8%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.33 | $-0.33 | $-0.33 | 5 |
| Q3 FY2028 | $-1.03 | $-1.03 | $-1.03 | 10 |
| Q2 FY2028 | $-1.66 | $-1.66 | $-1.66 | 7 |
| Q1 FY2028 | $-2.51 | $-2.51 | $-2.51 | 5 |
| Q4 FY2027 | $-1.74 | $-1.74 | $-1.74 | 4 |
| Q3 FY2027 | $-3.67 | $-3.67 | $-3.67 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 6 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 3 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 5 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 3 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 7 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +10.6% | $338.07 | $333.28 | -1.42% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -12.0% | $328.93 | $331.61 | +0.81% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +2.6% | $171.75 | $164.64 | -4.14% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +2.6% | $54.09 | $51.09 | -5.55% |
| ▼ Q2 FY2025 | May 2, 2025 | -2.8% | $38.06 | $40.24 | +5.73% |
| ▼ Q1 FY2025 | Feb 28, 2025 | -6.5% | $65.03 | $38.60 | -40.64% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -36.8% | $72.73 | $71.87 | -1.18% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +26.9% | $51.82 | $52.24 | +0.81% |
Q2 FY2026-1.42%
Report Date
May 7, 2026
EPS Beat/Miss
+10.6%
Price Before
$338.07
Price After
$333.28
Q1 FY2026+0.81%
Report Date
Feb 19, 2026
EPS Beat/Miss
-12.0%
Price Before
$328.93
Price After
$331.61
Q4 FY2025-4.14%
Report Date
Nov 5, 2025
EPS Beat/Miss
+2.6%
Price Before
$171.75
Price After
$164.64
Q3 FY2025-5.55%
Report Date
Aug 4, 2025
EPS Beat/Miss
+2.6%
Price Before
$54.09
Price After
$51.09
Q2 FY2025+5.73%
Report Date
May 2, 2025
EPS Beat/Miss
-2.8%
Price Before
$38.06
Price After
$40.24
Q1 FY2025-40.64%
Report Date
Feb 28, 2025
EPS Beat/Miss
-6.5%
Price Before
$65.03
Price After
$38.60
Q4 FY2024-1.18%
Report Date
Nov 6, 2024
EPS Beat/Miss
-36.8%
Price Before
$72.73
Price After
$71.87
Q3 FY2024+0.81%
Report Date
Aug 13, 2024
EPS Beat/Miss
+26.9%
Price Before
$51.82
Price After
$52.24
Avg Beat Reaction-2.57%
Avg Miss Reaction-8.82%
Beat Rate4 / 8 quarters
Largest Move-40.64% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PRAX ends December
Praxis Precision Medicines, Inc. (PRAX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-3.20 — beating the analyst consensus of $-3.58 by +10.6%. The next PRAX earnings date is expected around September 1, 2026.
Each quarter, investors track PRAX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PRAX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PRAX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PRAX earnings · 5 questionsPraxis Precision Medicines, Inc.'s next earnings report is expected around September 1, 2026. PRAX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PRAX historically reports after market close (AMC).
PRAX earnings datewhen is PRAX earningsPRAX next earnings datewhen does PRAX report earningsPRAX earnings calendar
▸ Source: FMP · Praxis Precision Medicines, Inc. SEC filings · US GAAP · Praxis Precision Medicines, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026